Scientists at TU Braunschweig and DeveloGen AG receive Phoenix
Science Award 2009 for a publication
(Thomson Reuters ONE) - Göttingen, Germany, 9 October 2009. DeveloGen AG, a biotechnologycompany focused on the discovery and development of novel therapiesfor diabetes and other metabolic and endocrine disorders announcedtoday that a team of scientist who published an article in theJournal of Medicinal Chemistry in the field of beta cell regenerationwas awarded the renowned Phoenix Science Award 2009 in the categorypharmaceutical chemistry. The award is endowed with 10.000 Euro.The team of scientists from DeveloGen AG in cooperation with Prof.Conrad Kunick's laboratory at the Technical University Braunschweig,Germany, published results which demonstrate that small syntheticmolecules can promote the regeneration of insulin producing betacells. In cell culture experiments the team of scientistsdemonstrated that highly potent and specific glycogen synthase 3 betainhibitors are able to protect beta cells from apoptosis andstimulate their proliferation.Cord Dohrmann, CEO of DeveloGen AG, said: "Receiving the PhoenixScience Award is further confirmation of the worldwide leading workconducted at DeveloGen in the field of beta cell regeneration.Together with Prof. Kunick we were able to generate importantinsights about how beta cells can be protected from apoptosis andstimulated to proliferate. This is an important step towards thediscovery and development of innovative and potentially diseasemodifying therapies for the treatment of diabetes."The title of the publication is: "9-Cyano-1-azapaullone(Cazpaullone), a Glycogen Synthase Kinase-3 (GSK-3) InhibitorActivating Pancreatic Beta Cell Protection and Replication". Thearticle was published in April 2008 in the Journal of MedicinalChemistry.About DiabetesDiabetes is a global epidemic with devastating human, social andeconomic consequences. In 2007 it was estimated that 246 millionpeople worldwide have diabetes, representing roughly 6% of the adultpopulation. The number is expected to reach 380 million by 2025,representing over 7% of the adult population. Diabetes/obesity is thefastest growing disease in the USA, afflicting one in four Americansand accounting for well over 30% of the Medicare budget.About DeveloGen AGDeveloGen AG is a biopharmaceutical company engaged in the discoveryand development of novel therapeutics for the treatment of metabolicand endocrine diseases. The Company has a highly innovative and deeppreclinical discovery pipeline addressing the key drivers in thedevelopment of diabetes and obesity such as insulin resistance andloss of insulin-producing beta cells. This pipeline includes programsfor the potential treatment of obesity through orally available smallmolecules based on novel and proprietary targets as well as growthfactors targeting beta-cell regeneration (type 1 and type 2diabetes). In addition, the Company is developing DG3173(Somatoprim), a potentially best-in-class somatostatin analogue forthe treatment of acromegaly, carcinoid tumors and diabeticretinopathy, which has recently successfully completed a Phase 1clinical trial. DeveloGen is based in Göttingen, Germany. For moreinformation on DeveloGen, please visit www.develogen.com.About Phoenix Science Award ("Phoenix Wissenschaftspreis")Each year, Phoenix Pharma AG awards a price for scientific work inthe areas pharmacology, pharmaceutical biology, pharmaceuticalchemistry and pharmaceutical technology, which has been published ina German or English journal.- ends -ContactDeveloGen AGCarsten DehningChief Financial OfficerMarie-Curie-Straÿe 737079 Göttingen, GermanyPhone: +49 551 50558 514Fax: +49 551 50558 586dehning(at)develogen.comThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 09.11.2009 - 08:30 Uhr
Sprache: Deutsch
News-ID 8095
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 275 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Scientists at TU Braunschweig and DeveloGen AG receive Phoenix
Science Award 2009 for a publication "
steht unter der journalistisch-redaktionellen Verantwortung von
DeveloGen AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
